TH25170A - Recombinant vaccine of live bird species using avian herpes virus as vector. - Google Patents

Abstract

Avian recombinant vaccine based on avian herpesvyrnus That includes one or more nucleotide sequences coded for and characterizing the antidote. Bird germic genyl polypeptide is a vector The implantation into the region between ORF UL55 ATG and the U-interface and adjacent repetitive regions under the control of CMV, the implantation promoter vector should be selected from the Maret-pathogenic virus group ( MDV and HVT), laryngeal and laryngeal viruses, ILTV and duck herpes virus. A polyvalent vaccine formula containing at least two vaccines. Of these types that differ in the order of insertion

Claims (7)

1. Live recombinant avian vaccines that include Bird herpes virus Containing One or more nucleotide sequences coded for and characterizing. Antigenic polypeptide of avian disease virus is vector And the implant in the region between the ORF UL55 ATG and the UL appendage with an adjacent duplicate. 2. Live avian combinant vaccine, according to claim 1, where the nucleotide sequence was determined by the nucleotide sequence. It is regulated by CMV, the promoter of RNA 1.8 promoter 3. The avian combinant vaccine according to claim 1, which has the characteristics that The vector is selected from the group consisting of Marek Virus (MDV and HVT), Larynx and Larynx Inflammatory Viruses, ILTV, and Duck Herphies Virus 4. The avian combinant vaccine according to claim 3, which is characterized by the vector, is the HVT virus and the implant is performed in BamHI, I part. 5. The combinant vaccine with Live bird life according to claim 4, which is characterized by the penetration Make one in Intergenic area 1,2 and 3, or in BamHI's ORF UL55, part I 6. Live avian combinant vaccine according to claims 1 to 5, which has Characteristic that the CMV Informer promoter is the human HCMV IE promoter or the MCMV IE promoter of the rat 7. Avian combinant vaccine according to claims 1 to 6, which has Characteristic The implantable nucleotide sequence under the control of the CMV imedia promoter. It is a nucleotide sequence that processes the B-binding of selective antigens from the group of Gumboro disease antigens, Marek's disease, Newcastle disease, Bronchitis, Compression of Muddled sound and 8. Avian Laryngeal Live Vaccine in accordance with Clause 1 to 7, which has Characteristics of the implantable Jewish Cleotide sequence under control of CMV In Media Promoter It is a nucleotide sequence that is coded of the VP2 polypeptide of the IBDV virus. 9. The avian combinant vaccine according to claims 1 to 8, which has Its unique features include promoters that are integrated into CMV. In-Media Promoter that The body was arranged in a head-to-tail manner, in the latter case two nucleotide sequences were inserted. Into the insertion area One is under the control of CMV, another imie media promoter. It is under the control of the co-promoter 1 0. avian combinant live vaccine according to claim 9, which is characterized by The promoter is used together as a 1.8 RNA, Marek's promoter 1. 1. Any active avian vaccine pursuant to Claims 9 through 10 which has The characteristics that the implantable nucleotide sequence is under control of CMV The promoter is a nucleotide sequence that implements the code of the IBDV virus VP2 polypeptide, and where the nucleotide sequence inserted under the control of the right promoter is combined into a nucleotide sequence. Tide Code of the antigens of other bird diseases 1 2. The avian combinant vaccine pursuant to claim 11, which has a specific sequence. Nucleotides that code the antigen of other bird diseases selected from Marek's disease antigens, Newcastle disease, bronchial inflammation, tube compression. Sound and larynx and impulse from birds 1 3. The avian combinant vaccine according to claim 9, which is unique in that The promoters that are used in conjunction are CMV invoices that come from different sources. 4. Any active avian vaccine according to Claims 1 through 13, which has A characteristic in which one or more implanted nucleotide sequences are selected from the sequence group. With the code of China as follows; -VP2, VP3 and VP2 + VP4 + VP3 of Borovirus-gB, gC, gD and gH + gL of Marek Pathogenic Viruses, -VP1 (52kDa) + VP2 (247kDa) of Malitus Viruses. From birds - S and M of fusible pathogens and -gB, gC, gD and gH + gL of pharyngeal and laryngeal-causing viruses 1 5. Any active avian vaccine according to claims 1 to 15, which has Characteristic that uses 1.8 RNA promoter instead of CMV promoter promoter 1 6. Polyvalent vaccine formulation containing live recombinant vaccine. Of at least two bird species in the form of a mixture or to be blended as defined in either Clause 1 to 15, where these vaccines include Different insertion order 1 7. Live avian combinant vaccine according to claim 16, which is specific to the sequence. Different implant nucleotides are caused by different pathogens.